Dutetrabenazine: Completed Phase II/III enrollment

Auspex completed enrollment of about 90 patients in the double-blind, placebo-controlled, international Phase II/III ARM-TD trial evaluating SD-809 for 12 weeks. Patients who complete the trial may en...